Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Non-Hodgkin Lymphoma | Sickle Cell Disease | Acute Myeloid Leukemia | Myelodysplatic syndromes | Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Anaplastic Astrocytoma
Age: Between 0 - 100 Years
Gender: Male or Female
Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.
Any planned conditioning regimen and GVHD prophylaxis approach is eligible.
Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.
Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required